Background
Methods
CIRCUS is an international, prospective, multicenter, randomized, double-blinded, placebocontrolled trial. The study is designed to compare the efficacy and safety of cyclosporine versus placebo, in addition to revascularization by PPCI, in patients presenting with acute anterior myocardial infarction within 12 hours of symptoms onset and initial TIMI flow≤1 in the culprit left anterior descending coronary artery. Patients are randomized in a 1:1 fashion to 2.5mg/kg intravenous infusion of cyclosporine or matching placebo performed in the minutes preceeding PCI. The primary efficacy endpoint of CIRCUS is a composite of 1-year all-cause mortality, rehospitalization for heart failure or heart failure worsening during inital hospitalization, and left ventricular adverse remodelling as determined by sequential transthoracic echochardiography. Secondary outcomes will be tested using a hierarchical sequence of left ventricular (LV) ejection fraction and absolute measurements of LV volumes. The composite of death and rehospitalization for heart failure or heart failure worsening during inital hospitalization will be further assessed at three years after the initial infarction. 
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Conclusions
The CIRCUS trial is testing the hypothesis that cyclosporine in addition to early revascularization with PPCI compared to placebo in patients with acute anterior myocardial infarction reduces the incidence of death, heart failure and adverse LV remodelling at one-year follow-up.
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Background
Studies have demonstrated that infarct size is a major determinant of prognosis after AMI 1, 2 .
Interventions aimed at reducing infarct size might therefore be of major clinical interest to improve the outcome of AMI patients. Timely reperfusion by primary percutaneous coronary intervention is the standard of care for AMI 3 . The progress in the access to and efficiency of primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI) patients during the last decade is one of the main factors underlying the improvement in STEMI patients clinical outcomes 4 .
However, experimental and clinical reports indicate that reperfusion has deleterious effects, including myocardial stunning, induction of ventricular arrhythmias, no reflow and lethal reperfusion injury 5, 6 . Irreversible damage occurring after reperfusion may account for up to 40%
of the final infarct size 7 .
Accumulating evidence suggests that cardiomyocyte mitochondria play a key role in lethal reperfusion injury [8] [9] [10] [11] . The opening of a nonspecific high conductance channel (called the mitochondrial permeability transition pore) in the inner mitochondrial membrane results in the collapse of the membrane potential, the uncoupling of the respiratory chain, the release of cytochrome c and other proapoptotic factors and the depletion of ATP; these metabolic alterations may lead to cardiomyocyte death 12 . Calcium overload and excessive production of reactive oxygen species caused by sudden reperfusion of the ischemic myocardium can trigger the opening of the mitochondrial permeability transition pore 9, [12] [13] [14] .
In addition to its well-known immunosuppressive properties, cyclosporine is a potent inhibitor of mitochondrial permeability transition pore 15 . Several reports indicate that cyclosporine given at the time of reperfusion limits lethal reperfusion injury under experimental conditions 9, [16] [17] [18] .
Recently, a small proof-of-concept clinical study in STEMI patients showed that cyclosporine given immediately prior to reperfusion could reduce infarct size as measured by CMR by approximately 20% 19 .
This underlines the need for a phase III randomized trial to address the clinical efficacy of cyclosporine in addition to PPCI for acute myocardial infarction patients. The CIRCUS trial was designed to test the hypothesis that a single intravenous administration of cyclosporine immediately before PCI reduces the 1-year composite of mortality, rehospitalization for heart failure or heart failure worsening during initial hospitalization, and left ventricular remodelling in anterior STEMI patients referred for PPCI.
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Study objectives
In the CIRCUS trial, patients with anterior STEMI undergoing PPCI are randomized to a single intravenous bolus of 2.5 mg/kg of cyclosporine (CiclomulsionÒ, NeuroVive Pharmaceutical AB, Lund, Sweden) or 2.5 mg/kg of matching placebo.
The primary objective of the study is to determine whether the administration of a single intravenous bolus of cyclosporine before reperfusion compared to placebo in patients with large amounts of myocardium at risk (anterior STEMI) results in reduced incidence of all-cause mortality, rehospitalization for heart failure or heart failure worsening during initial hospitalization and adverse left ventricular (LV) remodelling as assessed by transthoracic echocardiography at 1-year follow-up. Adverse LV remodelling is defined here as an increase in LV end-diastolic volume (LVEDV) ≥ 15% between the initial LVEDV and follow-up LVEDV at one-year.
The reasons for choosing this primary objective are:
-all-cause mortality is a hard clinical endpoint and in the first-year following anterior MI, the main cause of death is of cardio-vascular origin. In addition, in this off-label use of cyclosporine, it appeared mandatory to have all-cause death as an endpoint. This is to account for any potential unexpected cardiac or extra-cardiac effects of cyclosporine.
-heart failure events are closely related to the amount of myocardial tissue damage induced by the ischemic and reperfusion injuries 2 . As our primary hypothesis is that cyclosporine significantly reduces infarct size, we expect a significant reduction of heart failure events after AMI.
-adverse LV remodelling is closely related to the final infarct size 20 . If cyclosporine significantly reduces the final infarct size, it should also reduce the adverse LV remodelling M A N U S C R I P T ACCEPTED MANUSCRIPT 7 process. The link between the adverse remodelling process and hard clinical events is unclear.
The long-term follow-up at 3-years of the CIRCUS study should provide evidence for this
relationship.
An important secondary objective is to evaluate the clinical outcome at 36 months defined by the composite endpoint of death and rehospitalization for heart failure or heart failure worsening during inital hospitalization.
Study population and patient selection
The CIRCUS study is a prospective, randomized, international, multicenter, placebo-controlled trial in patients with anterior acute STEMI referred for PPCI.
The study is ongoing in 57 centers in France, Belgium and Spain. The study is being performed The main inclusion and exclusion criteria are listed in Table 1 .
Consent was obtained in an emergency setting. In all centers, patients were informed as soon as possible of the ongoing trial prior to coronary angiography. The angiogram was performed to collect TIMI flow data. If the selection criteria were completed, then the informed consent was
If the written informed consent could not be obtained, an oral informed consent was obtained and ascertained by an impartial witness, independent of study investigator, or a patient's legal representative or relative. In the latter case, the study investigator obtained the patient's written informed consent as soon as possible after randomization.
Randomization and treatment protocol
The investigation schedule is depicted in Figure 1 and the study flow chart is shown in Table 2 .
Patient randomization was performed centrally by internet after secure login into the on-line casereport form (CRF) of the study, with a randomization ratio of 1:1 using a computer-based randomization program, stratified by center.
All patients received revascularization by PPCI plus medical treatment according to guidelines 3 .
During PCI, the choice of stent (bare-metal or drug-eluting stent) was left to the discretion of the operator. The use of thrombus aspiration, intra-coronary glycoprotein IIb/IIIa inhibition and devices to prevent distal embolization was left to the discretion of the operator.
After coronary angiography but before angioplasty, patients who met the enrolment criteria were randomly allocated to either the placebo or the cyclosporine group. Before the first balloon inflation, patients received an intravenous bolus injection of 2.5 mg/kg of the study drug. For each group, the study drug was injected slowly (over 2 to 3 minutes) via a catheter positioned within a peripheral vein.
The investigational medicinal product is cyclosporine (CiclomulsionÒ, NeuroVive
Pharmaceutical AB, Lund, Sweden) 21 . The matching placebo of CiclomulsionÒ (NeuroVive Pharmaceutical AB, Lund, Sweden) is a lipid emulsion composed with refined soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, M A N U S C R I P T ACCEPTED MANUSCRIPT 9 water for injection). The qualitative composition of CiclomulsionÒ and its placebo only differed by the presence or absence of cyclosporine. The final emulsions were visually indistinguishable.
All study procedures are detailed in Table 2 . 12-lead electrocardiogram, coronary angiography and echocardiographic data procedures are presented below.
Assessment of the clinical outcomes will be performed by 3-telephone interviews at 30-day, 3-month and 6 month follow-up. The primary outcome will be measured during a routine cardiology visit performed at 1-and 3-years.
Electrocardiogram (ECG)
For all patients five 12-lead ECGs will be obtained at admission (before PCI), after PCI (60 to 90 minutes after PCI), at hospital discharge, at 1 year (±8 weeks) and 3 years (±8 weeks). All ECG recordings will be sent to the coordination center for a centralised reading in the CIRCUS ECGcore laboratory. Expert readers will assess the maximal ST-segment deviation in the anterior leads and the number of significant Q waves for each recording.
Coronary Angiography
For all patients, the coronary angiography performed at admission will be stored digitally and sent to the coordinating center for centralized reading. All angiographic data will be analyzed on a specific workstation (Osirix) by a single expert observer blinded to all other clinical data. Site of occlusion, initial and final TIMI flow, collateral circulation (Rentrop grade), stent number, multi-vessel disease status, coronary interventions and complications, angiographic estimate of the area at risk size (APPROACH score 22 ) will be assessed for each patient. M A N U S C R I P T
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Cardiac biomarkers
For all patients, at least two blood samples for cardiac biomarkers (total creatine kinase (CK), troponin T or I) will be performed and measured locally. Biomarkers will be assessed at admission and at 4 hours (±30 minutes) after reperfusion.
Transthoracic Echocardiography
For all patients, conventional transthoracic echocardiography will be performed in all patients after PCI during the index hospitalization (within the first week following admission), at one year (±8 weeks) and 3 years (±8 weeks) after AMI.
Patients are scanned in the left supine position from an apical window. Images are obtained using Left ventricular volumes are measured and the biplane Simpson's rule is applied 23, 24 . LV remodelling will be assessed at 1 year (±8 weeks) versus baseline echocardiography (48 hours ± 48 hours) according to the following formula:
(LVEDV 1 year-LVEDV baseline/ LVEDV baseline) x 100.
All echocardiographic data are stored digitally and sent to the coordinating center for a centralized corelab reading. Two blinded expert operators will centrally assess data on a specific workstation.
Primary and secondary end points
The primary end point is a composite of 1-year all-cause mortality, rehospitalization for heart failure or heart failure worsening during inital hospitalization, and left ventricular adverse remodelling as determined by sequential transthoracic echochardiography.
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Key secondary endpoints include LV ejection fraction (LVEF), LV end-diastolic and end-systolic volumes assessed within the first week following admission and at one and three years.
Secondary endpoints also include all individual components of the primary endpoint taken separately (all cause mortality; rehospitalization for heart failure or worsening of initial heart failure status during initial hospitalization; adverse LV remodelling).
Other secondary endpoints used in several previous STEMI trials 25, 26 are being examined across both arms. They include the following:
1) Major adverse ischemic cardiac events: unstable angina or reinfarction (using the universal definition of myocardial infarction definition 27 ) and unplanned revascularization by either PCI or coronary artery bypass graft;
2) Major adverse cardiac and cerebrovascular events;
3) Implantable cardioverter defibrillator implantation for primary or secondary prevention; 4) NYHA (New York Heart Association) dyspnea status at one and three years; 5) Incidence of complete ST-segment resolution 60±30 minutes after the last angiogram; 6) 4±2-hours post-admission levels of serum troponin and creatine kinase;
We did not have the means to assess the myocardial biomarker release kinetics after reperfusion conversely to our previous trial 19 . The sample size, the change in local routine practices and the heterogeneity of biomarker assays (especially for hypersensitive troponins) prevented us from comparing the biomarker release between both groups. Post-reperfusion LV arrhythmias (nonsustained and sustained ventricular tachycardia and ventricular fibrillation) will also be compared between both groups, as another exploratory endpoint.
Besides efficacy, the trial addresses the issue of safety of a 2.5 mg/kg cyclosporine intravenous bolus given immediately prior to reperfusion. Safety assessment includes acute renal failure as assessed by serial measurement of creatinine between baseline and 48 hours after admission and any other serious adverse events declared by investigational centers as being potentially related to investigative drug/placebo.
Substudy
The CIRCUS trial has one Cardiac Magnetic Resonance Imaging sub-population analysis. It plans to evaluate infarct size, microvascular obstruction, LV remodelling and LV systolic function recovery. This exploratory sub-population analysis will be performed only in centers fulfilling technical requirements and where CMR is available in routine practice 28, 29 . There is no prespecified sample size for this sub-population analysis.
Study monitoring and adjudication committee
An independent Data Safety Monitoring Board (DSMB) that includes one cardiologist, one pharmacologist and one bio-statistician will monitor the trial. The DSMB will receive the results of two blinded interim analyses performed after 300 and 500 inclusions. Interim safety analyses will assess the one-month all-cause mortality and acute renal failure in both study groups. The DSMB will be entitled to make recommendations to the steering committee regarding the continuation of the study.
All clinical and safety endpoints will be adjudicated by a Clinical Endpoints Committee (CEC), blinded to the patients' assigned treatment, based on data provided by the investigational centers.
Study Funding
The CIRCUS trial is an investigator-initiated trial that is supported by a national PHRC program funded by the French Ministry of Health (PHRC National 2010). Furthermore, it is supported by grants from NeuroVive Pharmaceutical AB, Lund, Sweden, that also provides the study treatment CiclomulsionÒ and matching placebo.
Statistical design
We estimated that the proportion of patients reaching the endpoints (death, hospitalization for heart failure (HF), LV remodelling) in the control group over the planned 12 months of the study would be 7% for death and 42% for heart failure and LV remodelling combined. The expected proportion of the combined endpoint was estimated to 49 % taking into account the overlap of heart failure and LV remodelling. An estimated 790 patients (395 patients per group) would be required for the study to have 80% power to detect a 20% reduction in the relative risk with a two-sided alpha level of 5%. We estimated that the assessment of LV remodelling would be missing for 14% patients surviving at 1 year, and the sample size was increased to adjust for missing values. In addition, a further 10% was added to accommodate the fact that the sample size was calculated assuming the use of a chi-square test while a different model will be used for the analysis. The final sample size was estimated to 972 patients. The sample size was calculated using nQuery+nTerim 2.0.
The primary analysis will be a modified intention-to-treat (mITT) analysis including all randomized patients with a valid measurement for the primary endpoint. Patients will be analysed in the treatment group to which they were allocated by randomization. M A N U S C R I P T
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For the primary endpoint, data will be analysed by comparing the proportion of the primary combined efficacy endpoint at 12 months in the active group vs. the placebo group by using a logistic mixed effect regression model that includes treatment as fixed effect and center as random effect.
A hierarchial approach will be used to adjust for multiple testing of the first five endpoints: a) Combined incidence of (death, heart failure and increase in LVEDV > 15 % at one year), The abovementioned endpoint e), time to first event (death, hospitalization for heart failure) is classified as an additional primary endpoint at 36 months but will follow as endpoint number five in the hierarchial testing. This since the other endpoints in the hierarchy will be analysed and reported at 12 months. Each subsequent test will only be considered as confirmatory providing the previous step(s) is/are successful at the 5%-level (p<0.05). If any of the previous steps is not successful, the analysis of the following steps will be considered descriptive.
Treatment difference in EF at 12 months, LVEDV at 12 months and LVESV at 12 months will be estimated and analysed using mixed linear models that include treatment as fixed effect and centre as random effect. Other covariates may be added for additional analyses of the secondary endpoints. Where applicable, non-parametric methods may be considered as alternative approach for some of the endpoints. M A N U S C R I P T
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For each component of the primary endpoint and for secondary clinical outcomes endpoints such cardiovascular mortality, myocardial infarction, unstable angina, stroke, descriptive methods without formal statistical testing will be used.
The primary analysis of CIRCUS is conducted at 12 months and at 36 months a follow-up analysis will be performed. The purpose of the 36-month analysis is to gain additional power for an additional combined endpoint of hard outcomes: time to first event [all-cause mortality, hospitalization for heart failure] at three years post-AMI. 
Study organization
The The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
Discussion
CIRCUS is the largest prospective phase III randomized trial assessing the impact of a single injection of cyclosporine compared to placebo just before revascularization on a composite endpoint of all-cause mortality, rehospitalization for heart failure, and echocardiographic LV remodelling at 1-year follow up in acute STEMI patients referred to PPCI. 33, 34 . This contributed to confirm the existence of lethal reperfusion injury in STEMI patients and eventually to consider its treatment 35 .
As a matter of fact, several small-size proof-of-concept studies have demonstrated that ischemic conditioning interventions, administered before, or immediately at the onset of reflow, were able to reduce infarct size, attenuate myocardial no-reflow and edema and improve functional recovery 33, 36, 37 . Because ischemic postconditioning by coronary angioplasty is not always easy to handle (thrombotic burden, complex tortuous coronary anatomy), some investigators examined whether pharmacological agents might mimic ischemic postconditioning.
Piot et al.
were the first to demonstrate that a single bolus intravenous administration of cyclosporine prior to PCI reperfusion could reduce infarct size in STEMI patients 19, 38 . However, another trial failed to find benefit of cyclosporine in combination to thrombolysis 39 . In the MitoCare trial, administration of TRO40303, an agent that binds the outer mitochondrial membrane but does not act directly on the mitochondrial permeability transition pore, failed to reduce infarct size in STEMI patients 40 .
In a follow-up study of the Piot's trial, Mewton et al. reported that patients who received cyclosporine immediately prior to PCI developed less adverse LV remodelling and displayed
improved LV function at 6 months post-infarction 38 . In addition, recent phase II trials have demonstrated that other pharmacological agents, administered prior to reperfusion, may reduce infarct size in STEMI patients, including intra-coronary abciximab, metoporolol or the GLP-1 analog exenatide 26, 41, 42 .
However, these encouraging results remain of limited clinical relevance. A pragmatic and sufficiently powered trial assessing a cardioprotective intervention on well-defined clinical endpoints is needed for the confirmation of a significant clinical benefit and future implementation on a routine basis. The CIRCUS trial was thus designed with the primary objective to examine the potential benefit of cyclosporine on outcomes after STEMI.
Beyond the evaluation of the impact of cyclosporine on clinical endpoints, the results are also expected to shed further light on the role of LV remodelling as a determinant of post-AMI heart failure 20, 30 . At 36 months, a composite endpoint of death and rehospitalization for heart failure or worsening of heart failure during initial hospitalization will be analysed as a key secondary endpoint. The longer follow-up will yield power for this more conventional endpoint based
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The study population was defined in order to maximize the ability to detect a benefit of cyclosporine in preventing adverse clinical outcomes related to lethal reperfusion injury.
Cyclosporine, as well as ischemic conditioning interventions, is known to be of potentially greater benefit in patients with a large area at risk 16, 19, 38 . 
